Premium
Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma
Author(s) -
Krishnadasan Ravitharan,
Bifulco Carlo,
Kim Julie,
Rodov Sofya,
Zieske Arthur W.,
Vanasse Gary J.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06248.x
Subject(s) - follicular lymphoma , medicine , socs3 , follicular phase , lymphoma , lymph node , oncology , cohort , survival analysis , gastroenterology , cancer , suppressor
Summary The prognostic significance of SOCS3 protein expression was determined in de novo follicular lymphomas (FL) with t(14;18) and bcl‐2 overexpression. Presentation lymph nodes from 82 FL patients for whom clinical information was available were immunohistochemically segregated into SOCS3‐positive ( n = 42) or ‐negative ( n = 40) cohorts, and overall survival (OS) was analysed. SOCS3‐positive FL patients had a median OS of 10 years compared with 22 years in SOCS3‐negative patients ( P = 0·001, log rank test). After adjusting for Follicular Lymphoma International Prognostic Index subgroups, SOCS3 overexpression remained an independent predictor of decreased OS ( P < 0·001). These findings suggest that overexpression of SOCS3 may be an independent poor prognostic variable in patients with de novo FL.